Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2005-04-27
2009-08-18
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C530S350000
Reexamination Certificate
active
07575751
ABSTRACT:
Members of the TGF-β superfamily control many physiologic and pathophysiologic processes in multiple tissues and signal via type II and type I receptor serine kinases. Type II activin receptors are promiscuous and known to bind 12 TGF-β ligands including activins, myostatin, BMPs and nodal. Methods are described for the screening and identification of antagonist for TGF-β superfamily members, in particular activin-A antagonist.
REFERENCES:
patent: 4886747 (1989-12-01), Derynck et al.
patent: 5011691 (1991-04-01), Oppermann et al.
patent: 5013649 (1991-05-01), Wang et al.
patent: 5106748 (1992-04-01), Wozney et al.
patent: 5108922 (1992-04-01), Wang et al.
patent: 5116738 (1992-05-01), Wang et al.
patent: 5141905 (1992-08-01), Rosen et al.
patent: 5187076 (1993-02-01), Wozney et al.
patent: 5284763 (1994-02-01), Derynk et al.
patent: 5652337 (1997-07-01), Oppermann et al.
patent: 5658882 (1997-08-01), Celeste et al.
patent: 5965403 (1999-10-01), Celeste et al.
patent: 6027919 (2000-02-01), Celeste et al.
patent: 0222491 (1987-05-01), None
patent: 0376785 (1990-07-01), None
patent: WO-91/05802 (1991-05-01), None
patent: WO-91/18098 (1991-11-01), None
patent: WO-92/00382 (1992-01-01), None
patent: WO-93/00432 (1993-01-01), None
patent: WO-93/16099 (1993-08-01), None
patent: WO-94/01557 (1994-01-01), None
patent: WO-94/15949 (1994-07-01), None
patent: WO-94/21681 (1994-09-01), None
patent: WO-94/26892 (1994-11-01), None
patent: WO-94/26893 (1994-11-01), None
patent: WO-95/01801 (1995-01-01), None
patent: WO-95/01802 (1995-01-01), None
patent: WO-95/04819 (1995-02-01), None
patent: WO-95/10539 (1995-04-01), None
patent: WO-95/10635 (1995-04-01), None
patent: WO-95/16035 (1995-04-01), None
patent: WO-96/01316 (1996-01-01), None
patent: WO-96/01845 (1996-01-01), None
patent: WO-96/02559 (1996-02-01), None
patent: WO-96/14335 (1996-05-01), None
patent: WO-96/36710 (1996-11-01), None
patent: WO-97/00958 (1997-01-01), None
patent: WO-97/36926 (1997-10-01), None
patent: WO-98/22492 (1998-05-01), None
patent: WO-99/06445 (1999-02-01), None
Husken-Hindi P., et al. Monomeric activin A retains high receptor binding affinity but exhibits low biological activity. J. Biol. Chem. 1994, vol. 269, pp. 19380-19384.
Lin, SJ. et al. The structural basis of TGF-b, bone morphogenetic protein, and activin ligand binding. Reproduction. 2006. vol. 132, p. 179-190.
Lopez-Ilasaca M, et al. The angiotensis II type I receptor-associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensis II signaling. Molecular Biology, 2003. vol. 14, p. 5038-5050.
Bergholdt R, et al. Characterization of new polymorphisms in the 5′ UTR of the human interleukin-1 receptor type I (IL1R1) gene: linkage to type I diabetes and correlation to IL-1R1 plasma level. Genes and Immunity. 2001. vol. 1, p. 495-500.
Grant, ES, et al. The insulin-like growth factor type I receptor stimulates growth and suppresses apoptosis in prostatic stromal cells. Journal of Clinical Endocrinology and Metabolism. 1998. vol. 83, p. 3252-3257.
Arora et al., “Thescrewgene encodes a ubiquitously expressed member of the TGF-β family required for specification of dorsal call fates in theDrosophilaembryo,”Genes Dev., 8(21): 2588-2601, 1994.
Baloh et al., “Artemin, a Novel Member of the GDNF Ligand Family, Supports Peripheral and Central Neurons and Signals through the GFRα3-RET Receptor Complex,”Neuron, 21(6): 1291-1302, 1998.
Basler et al., “Control of Cell Pattern in the Neural Tube: Regulation of Cell Differentiation bydorsalin-1, a Novel TGFβ Family Member,”Cell, 73(4): 687-702, 1993.
Bootcov et al., “MIC-1, a novel microphage inhibitory cytokine, is a divergent member of the TGF-β superfamily,”Proc. Natl. Acad. Sci. USA, 94(21): 11514-11519, 1997.
Cate et al., “Isolation of the Bovine and Human Genes for Müllerian Inhibiting Substance and Expression of the Human Gene in Animal Cells,”Cell, 45: 685-698, 1986.
Genback accession No. NM—002192.
Kotzbauer et al., “Neurturin, a relative of glial-cell-line-derived neurotrophic factor,”Nature, 384(6608): 467-470, 1996.
Lin et al., “GDNF: A Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons,”Science, 260(5111): 1130-1132, 1993.
Lyons et al., “Vgr-1, a mammalian gene related toXenopus Vg-1, is a member of the transforming growth factor β gene superfamily,”Proc. Natl. Acad. Sci. USA, 86(12): 4554-4558, 1989.
Milbrandt et al., “Persephin, a Novel Neurotrophic Factor Related to GDNF and Neurturin,”Neuron, 20: 245-253, 1998.
Moos et al., “Anti-Dorsalizing Morphogenetic Protein is a novel TGF-β homolog expressed in the Spemann organizer,”Development, 121(12): 4293-4301, 1995.
Oda et al., “Molecular Cloning and Functional Analysis of a New Activin β Subunit: A Dorsal Mesoderm-Inducing Activity in Xenopus,”Biochem. Biophys. Res. Commun., 210(2): 581-588, 1995.
Padgett et al., “A transcript from a Drosophila pattern gene predicts a protein homologous to the transforming growth factor-β family,”Nature, 325(6099): 81-4, 1987.
Stenzel et al., “The Univin Gene Encodes a Member of the Transforming Growth Factor-β Superfamily with Restricted Expression in the Sea Urchin Embryo,”Dev. Biol., 166(1): 149-158, 1994.
Weeks and Mellon, “A Maternal mRNA Localized to the Vegetal Hemisphere in Xenopus Eggs Codes for a Growth Factor Related to TGF-β,”Cell, 51(5): 861-867, 1987.
Zhou et al., “Nodal is a novel TGF-β-like gene expressed in the mouse node during gastrulation,”Nature, 361(6412): 543-547, 1993.
Fischer et al., “Residues in the C-terminal region of activin A determine specificity for follistatin and type II receptor binding,”Journal of Endocrinology, 176(1):61-68, 2003.
Harrison et al., “An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors,”J. of Biological Chemistry., 279(27):28036-28044, 2004.
Harrison et al., “Identification of a functional binding site for activin on the type I receptor ALK4,”Journal of Biological Chemistry, 278(23):21129-21135, 2003.
Massague, “TGF-beta signal transduction,”Annual Review of Biochemistry, 67:753-791, 1998.
Choe Senyon
Fischer Wolfgang
Gray Peter
Harrison Craig
Vale Wylie
Fulbright & Jaworski LLP
Hissong Bruce D
Landsman Robert
Research Development Foundation
LandOfFree
Activin-A mutants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Activin-A mutants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activin-A mutants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4059650